Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
Public ClinicalTrials.gov record NCT01399372. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase II Randomized Study of Rituximab, Methotrexate, Procarbazine, Vincristine, and Cytarabine With and Without Low-Dose Whole-Brain Radiotherapy for Primary Central Nervous System Lymphoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and help kill them or carry cancer-killing substances to them. Others interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as methotrexate, vincristine sulfate, procarbazine hydrochloride, and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high energy x rays to kill cancer cells. It is not yet know whether rituximab and combination chemotherapy are more effective when given with or without radiation therapy in treating patients with primary central nervous system lymphoma. PURPOSE: This randomized phase II trial studies how well giving rituximab and combination chemotherapy with or without radiation therapy works in treating patients with primary central nervous system lymphoma.
Study identification
- NCT ID
- NCT01399372
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 91 participants
Conditions and interventions
Conditions
Interventions
- Rituximab Biological
- Cytarabine Drug
- Methotrexate Drug
- Procarbazine Drug
- Vincristine Drug
- low-dose whole-brain radiation therapy Radiation
Biological · Drug · Radiation
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2011
- Primary completion
- Mar 18, 2020
- Completion
- May 19, 2022
- Last update posted
- Jul 19, 2023
2011 – 2022
United States locations
- U.S. sites
- 44
- U.S. states
- 18
- U.S. cities
- 37
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham Cancer Center | Birmingham | Alabama | 35233 | — |
| The Kirklin Clinic at Acton Road | Birmingham | Alabama | 35243 | — |
| Saint Joseph's Hospital and Medical Center | Phoenix | Arizona | 85013 | — |
| Arizona Oncology-Deer Valley Center | Phoenix | Arizona | 85027 | — |
| Arizona Oncology Services Foundation | Scottsdale | Arizona | 85260 | — |
| Fresno Cancer Center | Fresno | California | 93720 | — |
| Kaiser Permanente-Rancho Cordova Cancer Center | Rancho Cordova | California | 95670 | — |
| Rohnert Park Cancer Center | Rohnert Park | California | 94928 | — |
| The Permanente Medical Group-Roseville Radiation Oncology | Roseville | California | 95678 | — |
| South Sacramento Cancer Center | Sacramento | California | 95823 | — |
| Kaiser Permanente Medical Center - Santa Clara | Santa Clara | California | 95051 | — |
| Kaiser Permanente Cancer Treatment Center | South San Francisco | California | 94080 | — |
| Penrose-Saint Francis Healthcare | Colorado Springs | Colorado | 80907 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| Saint Alphonsus Cancer Care Center-Boise | Boise | Idaho | 83706 | — |
| Northwestern University | Chicago | Illinois | 60611 | — |
| Rush University Medical Center | Chicago | Illinois | 60612 | — |
| Loyola University Medical Center | Maywood | Illinois | 60153 | — |
| Cadence Cancer Center in Warrenville | Warrenville | Illinois | 60555 | — |
| Maine Medical Center-Bramhall Campus | Portland | Maine | 04102 | — |
| Maine Medical Center- Scarborough Campus | Scarborough | Maine | 04074 | — |
| University of Maryland/Greenebaum Cancer Center | Baltimore | Maryland | 21201 | — |
| Saint Joseph Mercy Hospital | Ann Arbor | Michigan | 48106-0995 | — |
| West Michigan Cancer Center | Kalamazoo | Michigan | 49007 | — |
| Nevada Cancer Research Foundation CCOP | Las Vegas | Nevada | 89106 | — |
| Dartmouth Hitchcock Medical Center | Lebanon | New Hampshire | 03756 | — |
| Memorial Sloan Kettering Cancer Center at Basking Ridge | Basking Ridge | New Jersey | 07920 | — |
| Memorial Sloan Kettering Cancer Center Commack | Commack | New York | 11725 | — |
| Columbia University Medical Center | New York | New York | 10032 | — |
| Memorial Sloan-Kettering Cancer Center | New York | New York | 10065 | — |
| University of Rochester | Rochester | New York | 14642 | — |
| University of Cincinnati | Cincinnati | Ohio | 45267 | — |
| Case Western Reserve University | Cleveland | Ohio | 44106 | — |
| Cleveland Clinic Foundation | Cleveland | Ohio | 44195 | — |
| University Pointe | West Chester | Ohio | 45069 | — |
| Geisinger Medical Center | Danville | Pennsylvania | 17822 | — |
| American College of Radiology Imaging Network | Philadelphia | Pennsylvania | 19103 | — |
| Thomas Jefferson University Hospital | Philadelphia | Pennsylvania | 19107 | — |
| Geisinger Wyoming Valley/Henry Cancer Center | Wilkes-Barre | Pennsylvania | 18711 | — |
| M D Anderson Cancer Center CCOP Research Base | Houston | Texas | 77030 | — |
| M D Anderson Cancer Center | Houston | Texas | 77030 | — |
| Community Memorial Hospital | Menomonee Falls | Wisconsin | 53051 | — |
| Froedtert and the Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
| Waukesha Memorial Hospital | Waukesha | Wisconsin | 53188 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01399372, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 19, 2023 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01399372 live on ClinicalTrials.gov.